Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.
Jing Wang, Dongming Zhou, Chenglan Lv et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis compared maintenance strategies after initial treatment in previously untreated patients with diffuse large B-cell lymphoma (DLBCL), using randomized trials. Ten trials involving 3,830 patients evaluated seven maintenance options. Compared with no maintenance, lenalidomide and rituximab were associated with improved progression-free survival (PFS): HR = 0.71, 95% CI = 0.53-0.94, and HR = 0.77, 95% CI = 0.64-0.92, respectively. No maintenance strategy significantly improved overall survival. Evidence quality was low because of incoherence in the network.
Key findings
- Lenalidomide maintenance improved PFS versus no maintenance (HR = 0.71, 95% CI = 0.53-0.94).
- Rituximab maintenance improved PFS versus no maintenance (HR = 0.77, 95% CI = 0.64-0.92).
- Rituximab was associated with improved PFS24 (RR = 1.06, 95% CI = 1.02-1.11).
- No maintenance intervention significantly improved overall survival; subgroup analyses suggested particular benefit from rituximab in high-risk and male patients.
Why it matters
Maintenance strategies may extend disease control after initial immunochemotherapy for some patients with newly diagnosed DLBCL. The findings distinguish PFS benefits from overall survival, for which no significant improvement was demonstrated. Because the evidence was rated low quality, these comparative estimates should be interpreted cautiously rather than treated as definitive evidence of benefit.
What to keep in mind
The authors rated the evidence as low quality because of incoherence in the network meta-analysis.